Targeting Cancer

Melanoma: BRAF Inhibitor+Immunotherapy Increases Antitumor Activity

About 50 percent of patients with metastatic melanoma — some 4,000 people a year — have the BRAF mutation and can be treated with Zelboraf. More than 50 percent of them respond well to the drug, but the responses usually last only a few months. With immunotherapy, fewer patients respond, but the responses are more […]

New Melanoma Driver Genes Found In Largest DNA Sequencing Study to Date

A Yale study has sequenced 147 melanomas, painting the most comprehensive picture yet of the disease’s molecular landscape. The study appears in the July 29 advance online publication of Nature Genetics.

Computational Method Finds Gene-to-Gene, Drug-to-Drug Connections

By mining large datasets, researchers can better understand gene-gene, protein-protein, and drug/side-effect interactions.  Two recent publications in the journals BMC Bioinformatics and BMC Systems Biology, from researchers at the Mount Sinai School of Medicine, describe computational methods that enable scientists to identify and prioritize genes, drug targets, and strategies for repositioning drugs that are already on the market. […]

Colon Cancer Genome Analysis Reveals New Targets

Work appearing in the July 19th issue of Nature reports a comprehensive genomic analysis of colon and rectal cancer, combining data from 276 tumor samples. Involving more than 150 researchers at dozens of institutions, the analysis found new markers for aggressive tumors, along with uncovering an important role for the regulator gene MYC. The team also […]

CollabRx apps discussed in the British Journal of Healthcare Computing

The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy […]

Gene Inactivation Drives Spread of Melanoma

CHAPEL HILL, N.C. – A team of UNC researchers have identified a key genetic switch that determines whether melanoma spreads by metastasis. In a paper published today in the journal Cancer Cell, a team from UNC Lineberger Comprehensive Cancer Center demonstrates that inactivating a gene called LKB1 (or STK11) causes non-aggressive melanoma cells to become highly […]

First Success of Targeted Therapy in Most Common Genetic Subtype of Non-Small Cell Lung Cancer

A novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study involved 87 […]

GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma

London UK — GlaxoSmithKline plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patients with BRAF mutation-positive metastatic cutaneous melanoma.

Researchers Create New Anti-cancer Drug Innovative Computer Modeling Techniques Utilized in Drug Development

HONOLULU- A team of University of Hawaii Cancer Center scientists have created a new type of anti-cancer drug, named BP-1-102 that targets a key protein that triggers the development of many types of cancer including lung, breast, and skin cancers. The development of BP-1-102 was guided by the research teams computer based molecular analysis of […]